BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients
Rhea-AI Summary
BriaCell (Nasdaq:BCTX) reported that its pivotal Phase 3 Bria-ABC study of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer has screened over 315 and enrolled over 230 patients. The trial’s primary endpoint is overall survival, with interim topline data expected in 2026 after 144 events. The Bria-IMT regimen holds FDA Fast Track status and has attracted growing interest from leading cancer centers, including independent highlight in a Nature Medicine article on trials expected to shape medicine in 2026.
AI-generated analysis. Not financial advice.
Positive
- Over 230 patients enrolled and more than 315 screened in Phase 3 Bria-ABC trial
- Interim topline overall survival data expected in 2026
- Trial design targets full approval of Bria-IMT in metastatic breast cancer if OS is positive
- Bria-IMT combination regimen has FDA Fast Track designation
- Increased interest from leading cancer centers supports ongoing enrollment
- Independent inclusion among “Eleven clinical trials that will shape medicine in 2026” in Nature Medicine
Negative
- Regulatory approval depends on future positive overall survival results not yet available
- Interim analysis requires 144 death events, reflecting the severity of metastatic disease and time to readout
News Market Reaction – BCTX
On the day this news was published, BCTX declined 1.92%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BCTX was down 0.72% while peers were mixed: ADAP -17.57%, CYCC -5.84%, PRTG -10.39%, IMNN -0.73%, NXTC +0.20%. Moves do not show a clear sector-wide pattern aligned with BCTX.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 07 | Site expansion update | Positive | -1.2% | Added NYU Perlmutter Cancer Center as Phase 3 Bria-ABC clinical site. |
| Apr 27 | ASCO data preview | Positive | +3.9% | Announced six metastatic breast cancer data presentations at ASCO 2026. |
| Apr 20 | QOL/biomarker data | Positive | -9.3% | Presented Phase 3 quality-of-life and Phase 2 biomarker findings at AACR. |
| Dec 18 | Nature Medicine feature | Positive | +3.2% | Nature Medicine highlighted Bria-IMT Phase 3 as shaping medicine in 2026. |
| Dec 10 | SABCS 2025 data | Positive | -7.9% | Presented Phase 2 survival and interim Phase 3 biomarker data at SABCS 2025. |
Clinical trial headlines have often seen volatile and sometimes negative next-day moves despite generally positive scientific progress.
Over the past months, BriaCell has repeatedly updated investors on its Bria‑IMT metastatic breast cancer program. Prior clinical‑trial news included new Phase 3 sites (May 7, 2026), ASCO 2026 presentation plans (Apr 27, 2026), positive Phase 3 quality-of-life and Phase 2 biomarker data (Apr 20, 2026), and recognition by Nature Medicine in Dec 2025. Earlier, SABCS® 2025 data highlighted Phase 2 survival benefits and interim Phase 3 signals. Today’s enrollment milestone (>315 screened, >230 enrolled) extends that same Bria‑IMT Phase 3 trajectory toward the planned interim OS analysis.
Historical Comparison
Recent clinical-trial headlines for BCTX averaged a -2.26% next-day move, showing that even positive Bria-IMT updates can coincide with muted or negative trading reactions.
Clinical-trial news has tracked steady Bria-IMT Phase 3 advancement: from early patient consent and survival signals, to recognition in Nature Medicine, biomarker and QOL data at AACR and SABCS, additional sites, and now >315 patients screened and >230 enrolled toward the 144-event OS interim analysis.
Market Pulse Summary
This announcement highlights tangible progress in Bria‑IMT’s pivotal Phase 3 Bria‑ABC trial, with over 315 patients screened and more than 230 enrolled toward an interim overall survival analysis at 144 events expected in 2026. Compared with prior clinical‑trial headlines featuring QOL, biomarker, and survival data, this update focuses on trial execution and momentum. Investors may track enrollment pace, timing of interim OS readout, and how upcoming data align with prior Phase 2 signals.
Key Terms
phase 3 medical
immune checkpoint inhibitor medical
metastatic breast cancer medical
overall survival medical
fda fast track designation regulatory
clinicaltrials.gov regulatory
AI-generated analysis. Not financial advice.
- Over 315 patients screened and over 230 patients enrolled in BriaCell’s pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor in metastatic breast cancer
- Enrollment momentum continues with strong clinical site and patient interest
- Interim topline data expected in 2026
- Positive interim overall survival results could support potential approval of Bria-IMT in metastatic breast cancer
- BriaCell’s Bria-IMT combination regimen continues under FDA Fast Track designation
PHILADELPHIA and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that its pivotal Phase 3 Bria-ABC study has screened over 315 and enrolled over 230 patients. BriaCell anticipates reporting topline data in 2026.
BriaCell has received increased interest from leading cancer centers and continued enrollment momentum following the independent inclusion of its Phase 3 clinical trial in Nature Medicine’s article, “Eleven clinical trials that will shape medicine in 2026”. The Phase 3 Bria-ABC study is evaluating BriaCell’s lead clinical candidate, Bria-IMT, in combination with an immune checkpoint inhibitor versus physician’s choice of treatment in advanced breast cancer.
The interim analysis will be conducted after 144 patient events, defined as deaths, have occurred. Overall survival (OS) is the primary endpoint, and positive results could support full approval of Bria-IMT in patients with metastatic breast cancer. The Bria-IMT combination regimen has received FDA Fast Track designation.
“Sustained and new interest from world class institutions and their patients continues to drive remarkable patient engagement,” stated Dr. William V. Williams, BriaCell’s President & CEO. “We remain on track to report the interim analysis in 2026 while continuing to enroll patients and advance preparations for potential commercialization, with the goal of bringing our novel immunotherapy regimen to patients with metastatic breast cancer as efficiently as possible.”
For additional information on BriaCell’s pivotal Phase 3 study, please visit ClinicalTrials.gov NCT06072612 .
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/ .
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about ongoing patient enrollment in the pivotal Phase 3 clinical study of Bria‑IMT, the expected timing of interim analysis and topline data readout, and the potential for full approval and marketing authorization of the Bria‑IMT combination regimen, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements, such as those are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Investor Relations Contact:
investors@briacell.com
